the asset with the largest combination of probability of success,
proximity to launch and potential medical and commercial value. The
Company has decided to seek a commercialization partner for
cetrorelix, which, in this indication, has potential for base case
peak annual sales of over $500 million in the United States market
alone. After defining the critical path to registration, the Company
expects to launch cetrorelix in the BPH indication in 2011.
Furthermore, after optimization of formulation and trial design, the
company plans to move into Phase 2b in the endometriosis indication
and will announce timelines relative to this program in the near
future. As was announced in May 2007, the rights to cetrorelix in the
endometriosis indication were regained from Solvay. The decision to
proceed with development was made based on:
a) the proven safety and efficacy of Cetrotide(R)
b) the overall database from preclinical and clinical studies in
c) the large unmet medical needs and commercial opportunity in the
area of endometriosis.
Additionally, as with the BPH indication, AEterna Zentaris will
eventually seek a commercialization partner as cetrorelix has the
potential for base case peak annual sales of approximately
$200 million in the U.S. market alone in the endometriosis
AEterna Zentaris has established its cytotoxic conjugate, AEZS-108,
as its highest earlier-stage priority, and will therefore initiate a
Phase 2 trial with this compound in a both endometrial and ovarian
cancers before year end. The Company feels AEZS-108 has large market
opportunities that could compare to those for doxorubicin.
|SOURCE AETERNA ZENTARIS INC.|
Copyright©2007 PR Newswire.
All rights reserved